Abstract #0620

Cerebrovascular reactivity (CVR) as a potential biomarker in vascular cognitive impairment: relationship with cognition, clinical diagnosis, amyloid and tau proteins.

Sandeepa Sur¹, Zixuan Lin¹, Yang Li¹, Sevil Yasar², Paul Rosenberg³, Rita Kalyani², Abhay Moghekar⁴, Zheyu Wang⁵, Kaisha Hazel¹, George Pottanat¹, Cuimei Xu¹, Peter van Zijl^1,6, Jay Pillai^1,7, Peiying Liu¹, Marilyn Albert⁴, and Hanzhang Lu^1,6

¹Department of Radiology, Johns Hopkins University, Baltimore, MD, United States, ²Department of Medicine, Johns Hopkins University, Baltimore, MD, United States, ³Department of Psychiatry, Johns Hopkins University, Baltimore, MD, United States, ⁴Department of Neurology, Johns Hopkins University, Baltimore, MD, United States, ⁵Department of Oncology, Johns Hopkins University, Baltimore, MD, United States, ⁶F.M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Institute, Baltimore, MD, United States, ⁷Department of Neurosurgery, Johns Hopkins University, Baltimore, MD, United States

Is whole brain cerebrovascular reactivity (CVR) associated with cognitive function in subjects with cognitive impairment and normal cognition? In a cross-sectional study of 72 subjects, whole brain CVR as assessed with the BOLD response to a CO2 breathing challenge, was significantly associated with measures of cognitive function. These relationships remained after adjusting for cerebrospinal fluid biomarkers of Alzheimer’s disease pathology and measures of vascular risk. These findings suggest that whole brain CVR may be useful as a biomarker for assessing altered cognition resulting from vascular dysfunction separate from Alzheimer’s disease.

This abstract and the presentation materials are available to members only; a login is required.

Join Here